



Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

[Abstract](#)

[Introduction](#)

[Methods](#)

[Results](#)

[Conclusions](#)

[References](#)

Click Headings Above to
View Content

ABSTRACT

Develop and embed a GxP-aligned, role-defined programming workflow that reliably delivers high-quality, analysis-ready datasets under compressed timelines for pharmacometrics (PopPK; exposure–response including PK–Safety, PK–QT, PKPD, PK–Efficacy).

Approach:

Standardize data specifications, programming templates, and macros

Clarify touchpoints between pharmacometricians and programmers

Institute a robust QC/validation framework with traceability.

Impact:

Improves reproducibility and auditability, reduces rework, accelerates delivery, and enables efficient cross-functional collaboration and continuous improvement.



Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

INTRODUCTION

Pharmacometric analyses integrate biomarkers, disease understanding, and clinical data to inform dosing strategies and benefit–risk across development.

Programming for pharmacometrics supports business decisions, regulatory submissions, exploratory analyses, and publications for both small and large molecules.

Programming operates under GxP and GDPR, with timelines aligned to critical path and coverage across therapeutic areas.

Datasets often combine dosing and PK with selected safety and efficacy elements, enabling analyses such as PopPK and exposure–response (PK–Safety, PK–QT, PKPD, PK–Efficacy).

Typical deliverables include .csv and .xpt files compliant for submissions.





Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

METHODS

Pharmacometrics analysis-ready data set generation spans the entire period from intake through closeout.

Intake begins with the data request, resourcing, and scoping of the activity, referring study documents, followed by coordination with the pharmacometrician and study team.

Programming to produce a modeling ready data set, and quality checks - including addressing QC comments from the pharmacometrician and concludes with finalization of the request.

To make Pharmacometrics analysis ready dataset generation more agile and robust, strengthen the following levers, clarifying purpose, scope, ways of working, and success measures:

Kickoff meeting: This process brings the study programmer and statistician together with the pharmacometrician to clarify timelines and data requirements for each request. Engaging study teams at initiation align study deliverables with pharmacometrics deliverables, reduces ambiguity, and surfaces dependencies early. It also ensures transparent sharing of data specifications, facilitates resource planning, and establishes realistic milestones, enabling coordinated execution and timely delivery across functions while minimizing rework and avoidable delays through proactive, cross-functional collaboration.





Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

METHODS

Data standards: The data standards governance group, representing pharmacometricians and programmers, defines and curates standard variables across analyses and therapy areas. Meeting regularly, it reviews requests for new variables, approves additions, and updates the standards accordingly. These robust data standards drive consistency across projects, streamline analyses, enhance reproducibility and traceability, and enable seamless handovers between programmers. They also reduce rework, accelerate onboarding, and support high-quality, audit-ready deliverables.

Standard programming templates: Developed standard programming templates for multiple analysis ready datasets. Using agile programming techniques, the templates are easily customized and quickly adapted to new requirements. Embedded defensive programming to validate inputs, enforce assumptions, and catch edge cases early, improving reliability and maintainability. This approach streamlines handovers, enabling one programmer to take over another's work with minimal friction and clearer intent. To strengthen quality, the templates read required variables directly from the data specifications and run automatic checks to ensure no variables are missing or mis-typed from the data specifications. The result is faster development, fewer defects, and consistent, auditable deliverables across projects.





Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

METHODS

Standard macros: Developed a set of validated utility macros and functions for frequently needed derivations, including BMI, Last Observation Carried Forward (LOCF), and duplicate key variable checks. These reusable, quality-checked standards streamline programming, reduce rework, and improve auditability. By applying the same logic across analyses, the validated macros ensure consistency in implementation and outputs, minimize inconsistencies across studies and datasets, and accelerate delivery timelines. This standardized toolkit supports project reproducibility, facilitates peer review, and strengthens compliance with programming standards.

Variable mapping specifications: This process enables early engagement with clinical study teams to define required safety and efficacy variables, align expectations, and map data specifications to source. By clarifying requirements upfront, it reduces last-minute surprises, improves cross-functional alignment, and ensures deliverables match study objectives. The standardized approach accelerates programming, streamlines derivations, and produces analysis-ready datasets more efficiently from clinical study data, supporting reproducibility, auditability, and timely delivery across studies and submissions while enhancing collaboration and accountability.





Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

METHODS

Data visualization and validation: Developed a reusable QC macro to evaluate analysis-ready datasets with visualizations - PK concentration profiles, time-varying covariates, and related summaries. It verifies derivations, detects outliers, missing values, and baseline covariate issues, and standardizes review steps. This macro accelerates data checks, improves traceability, and helps programmers quickly identify and resolve issues, sustaining consistent, high-quality datasets.

Issue log: The issue log records all data issues identified by the programmer and any clarification needed on derivations. It is shared with the pharmacometrician to obtain responses, capturing the issue/question, resolution, and resolution date. This ensures clear traceability of decisions. Reviewing logs reveals issue trends, informs solutions for common problems, and guides program enhancements to detect them earlier.





Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

METHODS

Data Request Tool (DaRT): DaRT is a web-based platform that centralizes and standardizes data lifecycle maintenance, warehousing, and enforcement of data standards. It generates standards-compliant SAS programming templates by analysis type, and provides audit-ready, end-to-end data requests and deliverable tracking. DaRT supports therapy area and analysis-specific data specifications, and captures rich request metadata, including studies, resource assignments, and timelines, ensuring consistent governance, transparency, and reliable delivery across projects.

Knowledge sharing and lessons learned: Host short debriefs after milestones and at study close; capture playbooks, FAQs, and exemplars (code + specs + outputs). Offer micro training on standards, macros, and templates; track adoption metrics.





Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

RESULTS

Defined PM–Programming touchpoints improved resource visibility and reduced rework via early joint review of design and data availability.

Standardized templates and validated macros shortened development cycles and increased consistency across projects and therapy areas.

A disciplined QC/validation framework improved data integrity, and controlled data movement simplified downstream analysis and compliance.

Collectively, these measures produced faster, more reproducible, audit-ready datasets supporting internal decisions and submissions.





Pharmacometrics Analysis Ready Dataset Generation Process: Data, Roles & Tools from a Programmers perspective

Srinivas Bachina¹, Kiran Kumar Kode², Dheeraj Rupani³, Hasi Mondal¹

[1] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, US

[2] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Barcelona, Spain

[3] Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Wilmington, US

Abstract

Introduction

Methods

Results

Conclusions

References

Click Headings Above to
View Content

#PharmaSUG2025

CONCLUSION

A GxP-aligned, end-to-end programming workflow enables timely, high-quality, reproducible pharmacometrics datasets that support exploratory work and regulatory pathways. Ongoing enhancements

Broaden standards for exposure–response use cases.

Expand automated diagnostics and validation visualizations.

Deepen integration with collaboration and request-tracking platforms to strengthen traceability and throughput.

REFERENCES

International Society of Pharmacometrics (ISoP). (2025, September 5). *Risk-Based Quality Control Strategies for Efficient Delivery of High-Quality Pharmacometric Datasets* [Webinar]. ISoP Learning Center

ACOP Poster: A Pharmacometrics Strategy for Ensuring Compatibility of Exposure-Response Analysis with Clinical Study Report: Enhancing Accuracy, Traceability, and Transferability Through Variable Mapping Specification (VMS)- Azar Shahraz

